A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

Recruiting

Phase 1

HB-2121A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

Sponsor:

Nielsen Fernandez-Becker

Code:

NCT07377565

Conditions

Celiac Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HB-2121

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-01. This information was provided to ClinicalTrials.gov by Nielsen Fernandez-Becker on 2026-04-20.